Introduction {#s1}
============

Neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD) occur in the later decades of life and have no curative therapy. Therefore, future treatments for these disorders must be administered over decades, which means that safety profiles of therapeutic targets are of utmost importance. The advent of alternative therapies such as antisense oligonucleotides, gene therapy and immunotherapy, together with traditional pharmacology have made it such that almost any molecule can be targeted. More and more, the extent to which a target is druggable hinges on the safety and specificity of its targeting over time.

We recently demonstrated that TRIM28 regulates the steady state levels of the neurodegeneration-driving proteins α-Synuclein (α-Syn) and tau ([@bib21]). However, given the critical roles of TRIM28 in mammalian development ([@bib3]), its tractability as a therapeutic target remains questionable. For instance, complete loss of *Trim28* in mice causes early embryonic lethality due to pre-implantation defects ([@bib3]), and specific deletion of this gene in the developing tissues cause a host of defects ([@bib4]; [@bib7]; [@bib26]). Moreover, haploinsufficiency of *TRIM28* is expected to have deleterious outcomes in humans (pLI = 1.00, ExAC; \[[@bib15]\]). This may be due in part due to the multiple functions of TRIM28 within the cell including the repression of endogenous retroviral elements, maintenance of pluripotency, epigenetics and mitophagy ([@bib2]; [@bib5]; [@bib19]; [@bib24]; [@bib29]). Given the importance of TRIM28 for development, it remains unclear whether TRIM28 is critical for adult brain function, and whether it may safely be targeted in adulthood. Specifically, two questions remain related to the targeting of TRIM28 pharmacologically: (1) Is there a pharmacologically tractable domain in TRIM28 that could be targeted by a drug? (2) Is genetic suppression of TRIM28 in the brain and throughout the body tolerated in adulthood? To test this, we performed studies to pinpoint the mechanism by which TRIM28 regulates α-Syn and tau and generated two animal models to disrupt Trim28 in vivo, thus establishing its druggability in adulthood.

Results and discussion {#s2}
======================

We previously found that TRIM28 regulates the post-translational stability of α-Syn and tau and that this effect is mediated by two critical cysteines in its RING domain (C65 and C68; \[[@bib21]\]). We hypothesized that TRIM28 may act as an E3 SUMO ligase ([@bib16]; [@bib18]; [@bib30]) toward α-Syn and tau via this domain for three reasons: (1) TRIM28 interacts only weakly with α-Syn and tau ([@bib21]) and is therefore unlikely to act solely as a stabilizing factor via these residues; (2) TRIM28 mediates the nuclear localization of α-Syn and tau and SUMOylation is thought to play a critical role in influencing subcellular localization ([@bib9]); and (3) Given the post-translational stabilization effect of TRIM28 on α-Syn and tau ([@bib21]), we surmised that SUMOylation may help prevent polyubiquitination, thus increasing their overall bioavailability. To test whether SUMOylation itself regulates the levels of α-Syn and tau, we inhibited the sole E2 SUMO ligase, UBC9, via RNAi and pharmacological inhibition (using Viomellein \[[@bib10]\]). We found that both approaches were sufficient to decrease α-Syn and tau, suggesting that SUMOylation indeed regulates their steady state levels ([Figure 1A](#fig1){ref-type="fig"}). We next asked whether TRIM28 mediates the SUMOylation of α-Syn and tau. We first tested this in cells and found that knockdown of endogenous TRIM28 decreased native α-Syn and tau SUMOylation whereas ectopic overexpression of TRIM28 increased their SUMOylation ([Figure 1B](#fig1){ref-type="fig"}). Interestingly, when we mutated a catalytic RING domain of TRIM28 (C65A/C68A), we could inhibit α-Syn and tau SUMOylation ([Figure 1B](#fig1){ref-type="fig"}). This was consistent with our previous findings that mutating this residue impeded α-Syn and tau stabilization and nuclear localization ([@bib21]). However, mutant TRIM28 (C65A/C68A) was less stable than its wildtype form in all assays. Thus, whether these findings are due to decreased SUMOylation or to a change in TRIM28 protein stability is difficult to discern. To further test whether Trim28 regulates α-Syn and tau SUMOylation, we performed SUMOylation assays on endogenous α-Syn and tau from brain lysates (under denaturing conditions) from wild-type and *Trim28^+/-^* mice. We found that α-Syn and tau SUMOylation were significantly reduced in *Trim28* haploinsufficient mice ([Figure 1C](#fig1){ref-type="fig"}).

![Trim28 mediates the SUMOylation of α-Syn and tau.\
(**A**) Blocking SUMOylation -- by either pharmacological inhibition using viomellein or siRNA-mediated suppression of the sole SUMO E2 ligase, UBC9 -- decreases α-Syn and tau levels by western blot. (**B**) SUMO assay in human cells reveals that TRIM28 mediates the formation of SUMO2 adducts on α-Syn and tau. This effect is lost upon mutation of the RING domain of TRIM28 (TRIM28-Mut). (**C**) In vivo SUMO assay from denatured mouse brain lysates of WT and *Trim28^+/-^* mice. *Snca^-/-^* and *Mapt^-/-^* mice and IP: IgG serve as negative controls. \*, \*\*, \*\*\* and ns denote p\<0.05, p\<0.01, p\<0.001 and p\>0.05, respectively.](elife-36768-fig1){#fig1}

TRIM28 has several important functions throughout the cell ([@bib4]; [@bib5]; [@bib6]; [@bib7]; [@bib16]; [@bib18]; [@bib24]), and its loss of function in mice is embryonic lethal ([@bib3]). We asked whether one of its domains can be specifically targeted for future therapeutic use without disrupting the others. Given that two conserved critical cysteine residues in its RING domain ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}) regulate TRIM28 function toward α-Syn and tau, we hypothesized that mutating residues critical for its endogenous catalytic activity would be the most promising approach. We therefore generated a knockin mouse carrying mutations in its RING domain ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}). We found that mutating these residues, despite decreasing α-Syn and tau levels significantly, caused a dramatic destabilization of TRIM28 protein ([Figure 1---figure supplement 1C--D](#fig1s1){ref-type="fig"}). Moreover, homozygosity for the these E3 mutant allele caused embryonic lethality, a feature consistent with the effects of a null allele. Thus, mutating the RING domain of TRIM28 decreases α-Syn and tau levels, but does so by disrupting its structure and stability ([Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}).

Since TRIM28 has critical roles in development, we next asked whether we could bypass these defects by knocking down Trim28 in the postnatal mouse brain ([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). We used an AAV carrying both an shRNA targeting *Trim28* and a YFP reporter. We found that the virus was widely expressed throughout the brain ([@bib13]) and that mice receiving an shRNA against *Trim28* had a 75% depletion of *Trim28* in their brain ([Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}). Importantly, these mice developed normally until at least 10 weeks of age. We evaluated cortical and hippocampal thickness and astrocytosis in these mice and did not note any significant defects ([Figure 2---figure supplement 1C](#fig2s1){ref-type="fig"}).

Given that synucleinopathies and tauopathies most often occur in the later decades of life, therapeutics should therefore accurately mimic this late-stage disruption. To test whether late stage inhibition of Trim28 is therapeutically tractable, we generated Trim28 adult knockout mice. This was done by crossing a whole body, tamoxifen-inducible Cre (*UBC-CreER^T2^*, \[[@bib23]\]) with mice carrying a floxed *Trim28* allele ([@bib3]). We waited until the animals were 8--12 weeks old before starting a 4 week tamoxifen regimen to ablate *Trim28* ([Figure 2A](#fig2){ref-type="fig"}). To our surprise, we found that adult depletion did not result in early lethality nor overt phenotypes. Instead, adult knockout mice lived for the duration of the study (over 40 weeks post-tamoxifen injection, [Figure 2B](#fig2){ref-type="fig"}). We tested whether Trim28 is effectively ablated in these mice and found that Trim28 levels were reduced by over 75% in each tissue tested (both at the RNA and protein level; [Figure 2C,D](#fig2){ref-type="fig"} and [Figure 2---figure supplement 2A--C](#fig2s2){ref-type="fig"}). Importantly, α-Syn and tau levels were also decreased in multiple brain regions, corroborating our previous findings using germline haploinsufficient mice ([@bib21]).

![Trim28 adult knockout mice are viable and demonstrate reduced α-Syn and tau levels.\
(**A**) Experimental approach to delete Trim28 from the adult body. (**B**) Kaplan-Meier survival curve of Adult knockout mice (*UBC-CRE^ERT2^; Trim28^flox/flox^* + TAM vs littermate controls). No significant differences in survival are observed. (**C**) qPCR analysis for Trim28 expression in midbrain (MB), cortex (CTX) and hippocampus (HIP) of Trim28 adult knockout mice and control littermates. (**D**) Western blot analysis of α-Syn, tau and Trim28 levels in hippocampi from Trim28 adult knockout mice and control littermates. In (**B**), *n* = 14--33 per group. In (**C** and **D**), *n* = 12--13 per group.](elife-36768-fig2){#fig2}

An important aspect of measurable safety margins in the depletion of a gene is its impact on neuronal function. To assess whether loss of Trim28 in adult mice impacts brain structure and function, we performed a battery of behavioral and histological tests. We found that Trim28 adult knockout mice behaved similarly to their control littermate counterparts in every test assayed. Specifically, no defects were observed in motor behavior, anxiety, perseverative movements and memory ([Figure 3A--H](#fig3){ref-type="fig"}). Consistent with this, we could not discern any gross histological defects nor signs of inflammation (as measured by GFAP immunoreactivity) in the brain ([Figure 4A--C](#fig4){ref-type="fig"}). We further tested Trim28 levels via immunostaining and found that, while Trim28 was highly expressed in the brain (confirming our western and qPCR results), it was depleted in the adult knockout ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}). A previous study highlighted several gene expression changes in mice lacking Trim28 in forebrain excitatory neurons starting from postnatal day 14 ([@bib12]). We tested the expression of these genes in the hippocampus using qPCR and found that, while the directionality of changes was consistent with the previous study, there was a broad dampening of this effect in the adult knockout mice ([Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}). This may be due to the later stage depletion of Trim28 or the incomplete deletion of Trim28 (there is 15--20% remaining in most adult knockouts) and may account for the slight behavioral abnormalities observed in the reported juvenile forebrain-specific Trim28 knockouts ([@bib12]) versus the whole-body adult Trim28 knockouts.

![Adult depletion of Trim28 does not cause behavioral abnormalities.\
Adult knockout mice and littermate controls were subjected to: (**A**) Open field assay where total distance, speed, vertical activity and time in center were measured over a period of 30 min. (**B**) Parallel rod footslip analysis where number of footslips and time spent immobile were measured on a grid over a period of 10 min. (**C**) Pole test where the time to turn and descend were measured to a mouse on top (facing upward) of a 18' pole. (**D**) Elevated plus maze measured the time spent in open vs. closed arms during a period of 10 min. (**E**) Pavlovian conditioned fear analysis in both context and cued settings (day 2). (**F**) Novel object recognition assay showing the discrimination index for identifying the novel vs. familiar object. (**G**) Hole poke analysis of repetitive behavior measuring the number of sequential nose pokes. (**H**) Rotarod analysis measuring the motor coordination and learning of mice over a period of four days. For each test, *n* = 5--33; ns denotes p\>0.05.](elife-36768-fig3){#fig3}

![Adult depletion of Trim28 does not cause pathological abnormalities in the adult brain.\
Representative photomicrographs of the cortex, hippocampus and cerebellum stained with (**A**) H and E and (**B**) GFAP. (**C**) Quantification of cortical and hippocampal width as well as normalized GFAP intensity. For each test, *n* = 3; ns denotes p\>0.05.](elife-36768-fig4){#fig4}

Given that the adult knockout affects the whole body, we examined regions of the body that could be vulnerable to Trim28 loss-of-function-induced toxicity. We assessed general morphology of the heart, liver and spleen and found no discernable defects in the adult knockout mice compared to littermate controls ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). Moreover, blood chemistry in these mice appeared normal ([Figure 4---figure supplement 3](#fig4s3){ref-type="fig"}).

Taken together, our study suggests that adult depletion of more than 75% of total Trim28 from the mouse body does not result in overt neurobehavioral phenotypes nor does it cause gross histological or biochemical defects. This is consistent with reports that deletion of TRIM28 in terminally differentiated muscle does not cause obesity ([@bib6]). These findings hold important implications for therapeutic targeting of Trim28 in diseases such as AD and PD where an inhibitor targeting TRIM28 may hold promise in the future with minimal side effects. Given the high expression of Trim28 in the adult mouse brain, additional characterization of these adult knockout animals will provide important insights into the potential of Trim28 downregulation in the context of disease; any physiological tradeoffs that may be incurred will thus be elucidated.

An important point of consideration moving forward into therapeutics is the mechanism by which TRIM28 regulates the steady state levels of α-Syn and tau. While our data suggest that TRIM28 forms a complex with α-Syn and tau ([@bib21]) and mediates their SUMOylation, we were not able to reconstitute this complex in a cell-free system, suggesting that other factors may be at play. Furthermore, while disruption of TRIM28 E3 ligase activity in vivo reduced α-Syn and tau levels, it likely did so by destabilization of TRIM28 itself. Thus, it is still unclear whether this inhibition represents a loss of enzymatic function or simply a structural loss. Further studies looking at the effect of this inhibition in adulthood or targeting other domains that may mediate TRIM28 SUMOylation may hold promise. For instance, the bromodomain of TRIM28 could be an alternative target given that a mutation in cysteine 651 to an alanine (C651A) reduces its SUMOylation activity on another target, VPS34 ([@bib30]). Alternatively, SUMOylation of α-Syn and tau via Trim28 may only be a partial or bystander effect. Additional studies in cell-free systems and in organisms will thus be crucial to look for factors that mediate this relationship to yield global mechanistic insight on regulation. Most importantly, this study highlights the importance of testing the loss of function of lethal variants in the adult. While databases such as ExAC and GnomAD ([@bib15]) offer a window into the pathogenicity of variants in development, it should not be the only factor guiding target selection; especially for neurodegenerative conditions where treatment will often only occur in the later decades of life.

Materials and methods {#s3}
=====================

  ---------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type (species)\      Designation                         Source or reference          Identifiers                 Additional information
  or resource                                                                                                               
  ---------------------------- ----------------------------------- ---------------------------- --------------------------- -------------------------------
  Strain, strain background\   *Trim28^E3MT^ (C66A, C69A, R72G)*   This study                                               Pure C57Bl/6J background
  (*M. musculus*)                                                                                                           

  Strain, strain background\   *Trim28^flox^ B6.129S2(SJL)-*\      Jackson laboratory           Stock \#018552              Pure C57Bl/6J background
  (*M. musculus*)              *Trim28tm1.1Ipc/J*                                                                           

  Strain, strain background\   *UBC-CreERT2 B6.Cg-Ndor1*\          Jackson laboratory           Stock \#007001              Pure C57Bl/6J background
  (*M. musculus*)              *Tg*(*UBC-cre/ERT2)1Ejb/1J*                                                                  

  Strain, strain background\   *FVB/NCrl*                          Charles River                Code \#207                  Pure C57Bl/6J background
  (*M. musculus*)                                                                                                           

  Strain, strain background\   *Trim28^+/-^*                       [@bib21];\                                               Crossing Jax stock \#018552\
  (*M. musculus*)                                                  this study                                               to \#006054

  Strain, strain background\   *Snca^-/-^ B6;129 × 1-Sncatm1*\     Jackson laboratory           Stock \#003692              
  (*M. musculus*)              *Rosl/J*                                                                                     

  Strain, strain background\   *Mapt^-/-^ B6.129 × 1-Mapttm1*\     Jackson laboratory           Stock \#007251              
  (*M. musculus*)              *Hnd/J*                                                                                      

  Cell line (*H. sapiens*)     293T                                ATCC                         CRL-3216                    

  Cell line (*H. sapiens*)     293T-shScram                        This study; shScram\                                     293 T cells infected with\
                                                                   from\                                                    retrovirus (pMSCV) harboring\
                                                                   [@bib21].                                                *shScramble*. Selected with\
                                                                                                                            1 µg/mL of puromycin for at\
                                                                                                                            least 1 week before\
                                                                                                                            commencing experimentation

  Cell line (*H. sapiens*)     293T-shTRIM28                       This study; shTRIM28 from\                               293 T cells infected with\
                                                                   [@bib21].                                                retrovirus (pMSCV) harboring\
                                                                                                                            *shTRIM28*. Selected with\
                                                                                                                            1 µg/mL of puromycin for at\
                                                                                                                            least 1 week before\
                                                                                                                            commencing experimentation

  Transfected construct\       *Flag-SUMO2*                        This study                                               
  (*H. sapiens*)                                                                                                            

  Transfected construct\       *pKH3-HA-TRIM28*                    Addgene                      \#45569                     
  (*H. sapiens*)                                                                                                            

  Transfected construct\       *pKH3-HA-TRIM28-C65A/*\             [@bib21]\                    \#92199                     
  (*H. sapiens*)               *C68A*                              [@bib21]; Addgene                                        

  Transfected construct\       *pKH3*                              Addgene                      \#12555                     
  (*H. sapiens*)                                                                                                            

  Transfected construct\       *AAV8-YFP-shScramble*               This study                   accgcctgaagtctctgattaa      
  (*M. musculus*)                                                                                                           

  Transfected construct\       *AAV8-YFP-shTrim28*                 This study                   ttgttgaactgtttgaacatgc      
  (*M. musculus*)                                                                                                           

  Antibody                     alpha-synuclein (C-20),\            Santa Cruz\                  sc-7011-R                   This antibody has been\
                               Rabbit polyclonal                   Biotechnology                                            discontinued.

  Antibody                     alpha-synuclein (Clone 42),\        BD Biosciences               610786                      
                               Mouse monoclonal                                                                             

  Antibody                     Tau, Rabbit polyclonal              Dako                         A0024                       

  Antibody                     Tau (Tau-5), Mouse\                 Abcam                        ab80579                     
                               monoclonal                                                                                   

  Antibody                     Trim28 (20C1), Mouse\               Abcam                        ab22553                     
                               monoclonal                                                                                   

  Antibody                     SUMO2/3, Rabbit\                    Abcam                        ab3742                      
                               polyclonal                                                                                   

  Antibody                     Flag (M2), Mouse\                   Sigma Aldrich                F1804                       
                               monoclonal                                                                                   

  Antibody                     UBC9, Goat polyclonal               Novus Biologicals            NB300-812                   

  Antibody                     Vinculin (hVIN-1), Mouse\           Sigma Aldrich                V9131                       
                               monoclonal                                                                                   

  Antibody                     GFAP (G-A-5), Mouse\                Sigma Aldrich                G3893                       
                               monoclonal                                                                                   

  Sequence-based reagent\      *Mkrn3-f*                                                        ccatggagaaatatgcgaca        
  (*M. musculus*), qPCR                                                                                                     

  Sequence-based reagent\      *Mkrn3-r*                                                        ctgagctgcatcccaagg          
  (*M. musculus*), qPCR                                                                                                     

  Sequence-based reagent\      *Tcf5-f*                                                         tgatgcaatccggatcaa          
  (*M. musculus*), qPCR                                                                                                     

  Sequence-based reagent\      *Tcf5-r*                                                         cacgtgtgttgcgtcagtc         
  (*M. musculus*), qPCR                                                                                                     

  Sequence-based reagent\      *Pcdhb6-f*                                                       gccactagaagggctcgaat        
  (*M. musculus*), qPCR                                                                                                     

  Sequence-based reagent\      *Pcdhb6-r*                                                       tgtctccacatctagctgcaa       
  (*M. musculus*), qPCR                                                                                                     

  Sequence-based reagent\      *Klhdc4-f*                                                       cctggacaaaagttgacatcc       
  (*M. musculus*), qPCR                                                                                                     

  Sequence-based reagent\      *Klhdc4-r*                                                       caaactccccaccgaagac         
  (*M. musculus*), qPCR                                                                                                     

  Sequence-based reagent\      *Stac2-f*                                                        tgtctactagaaatcggtagccaag   
  (*M. musculus*), qPCR                                                                                                     

  Sequence-based reagent\      *Stac2-r*                                                        agcgtcttgttctccacctg        
  (*M. musculus*), qPCR                                                                                                     

  Sequence-based reagent\      *Smad3-f*                                                        ctcttggagcacatcctggt        
  (*M. musculus*), qPCR                                                                                                     

  Sequence-based reagent\      *Smad3-r*                                                        gcccagctggaaatatgc          
  (*M. musculus*), qPCR                                                                                                     

  Sequence-based reagent\      *Cdkn1c-f*                                                       caggacgagaatcaagagca        
  (*M. musculus*), qPCR                                                                                                     

  Sequence-based reagent\      *Cdkn1c-r*                                                       gcttggcgaagaagtcgt          
  (*M. musculus*), qPCR                                                                                                     

  Sequence-based reagent\      *C1ql2-f*                                                        tcacgtaccacattctcatgc       
  (*M. musculus*), qPCR                                                                                                     

  Sequence-based reagent\      *C1ql2-r*                                                        tgttgctggcgtagtcgta         
  (*M. musculus*), qPCR                                                                                                     

  Sequence-based reagent\      *Snca-f*                                                         gaagacagtggagggagctg        
  (*M. musculus*), qPCR                                                                                                     

  Sequence-based reagent\      *Snca-r*                                                         caggcatgtcttccaggatt        
  (*M. musculus*), qPCR                                                                                                     

  Sequence-based reagent\      *Mapt-f*                                                         gagaatgccaaagccaagac        
  (*M. musculus*), qPCR                                                                                                     

  Sequence-based reagent\      *Mapt-r*                                                         gtgagtccaccatgtcgatg        
  (*M. musculus*), qPCR                                                                                                     

  Sequence-based reagent\      *Trim28-f*                                                       gctgctgccctgtctacatt        
  (*M. musculus*), qPCR                                                                                                     

  Sequence-based reagent\      *Trim28-r*                                                       cacactggacaatccaccat        
  (*M. musculus*), qPCR                                                                                                     

  Sequence-based reagent\      *S16-f*                                                          aggagcgatttgctggtgtgg       
  (*M. musculus*), qPCR                                                                                                     

  Sequence-based reagent\      *S16-r*                                                          gctaccagggcctttgagatg       
  (*M. musculus*), qPCR                                                                                                     

  Sequence-based reagent\      *siScramble*                        ThermoFisher\                AM4611                      
  (*H. sapiens*), siRNA                                            Scientific                                               

  Sequence-based reagent\      *siUBC9*                            ThermoFisher\                AM16708-120322              
  (*H. sapiens*), siRNA                                            Scientific                                               

  Chemical compound,\          Viomeillin                          BioViotica                   BVT-0359-C500               
  drug                                                                                                                      

  Chemical compound,\          N-ethylmaleimide (NEM)              Sigma Aldrich                E3876-5G                    
  drug                                                                                                                      

  Chemical compound,\          Tamoxifen                           Sigma Aldrich                T5648-5G                    
  drug                                                                                                                      
  ---------------------------------------------------------------------------------------------------------------------------------------------------------

Cell culture {#s3-1}
------------

Cell culture was performed as previously described ([@bib21]). Briefly, HEK293T cells (ATCC CRL-3216; RRID:[CVCL_0063](https://scicrunch.org/resolver/CVCL_0063), authenticated by manufacturer but not by researcher) devoid of mycoplasma were cultured in complete DMEM (DMEM +10% FBS+1 x antibiotic/antimycotic). Cells were plated in 6-well or 24-well plates for *SUMOylation assays* (see below) or siRNA and drug treatment, respectively. For the latter, cells were treated with 20 nM of indicated siRNAs or 10 µm Viomellein (or DMSO control) for 72 hr prior to lysis and western blot.

SUMOylation assays {#s3-2}
------------------

α-Syn and tau SUMOylation were assayed in cells as follows. Briefly, HEK293T cells were transfected with 3 µg Flag-SUMO2 and TRIM28 variants for 48 hr. Cells were harvested in cold PBS and spun down at 5,000 RPM for five minutes at 4°C. Cells were then lysed in SUMO lysis buffer (1% Triton X-100, 150 mM NaCl, 10 mM Tris pH 8.0, 10% glycerol, 20 mM N-ethyl maleimide and protease inhibitors \[Roche\]) for 40 min on ice with occasional vortexing. Cell debris were spun down at 15,000 RPM for 20 min at 4°C. Lysates were applied to Dynabeads (Protein G, 15 µL slurry) that were previously washed and then conjugated to 1 µg of antibody (α-Syn, C-20 Santa Cruz Biotechnology; discontinued; tau, tau-5 Abcam; RRID:[AB_304171](https://scicrunch.org/resolver/AB_304171)) and incubated with rotation for 2 hr at 4°C. This sub-threshold pull-down allowed us to bypass the regulatory effect of TRIM28 on α-Syn and tau. Bound proteins were vigorously washed (to remove any interactors which themselves may be SUMOylated) four times in 500 µL of SUMO lysis buffer and eluted for 10 min at 95°C for downstream western blot analysis. For each condition, either cell lines stably knocking down *TRIM28* (*shTRIM28*) or non-silencing (*shScramble*) were used. In addition, TRIM28, TRIM28-Mut and control constructs were co-transfected at 300 ng per well (1:10 ratio to SUMO concentration). Alternatively, Flag-SUMO2 was pulled down using Flag-M2 magnetic beads (20 µl slurry, Sigma; RRID:[AB_2637089](https://scicrunch.org/resolver/AB_2637089)) under denaturing conditions (first boiling the sample prior to the IP). Each SUMOylation assay was performed three independent times.

For the in vivo SUMOylation assay, mouse brains were harvested in RIPA buffer containing protease and phosphatase inhibitors (GenDepot). Samples were boiled for 5 min at 95°C, following which antibodies (2.5 µg) targeting α-Syn (C-20, SCBT) or Tau (Tau-5, Abcam) were incubated overnight with rotation at 4°C. Antibody-lysate complexes were bound to Dynabeads (25 µl, Protein G) for 2 hr at 4°C with rotation and then washed vigorously 5 × 1 mL in wash buffer (50 mM Tris pH 7.3, 170 mM NaCl, 1 mM EDTA, 0.5 % NP-40). Bound protein was eluted in Laemlli buffer at 85°C for 10 min. Lysates were run on SDS-PAGE followed by Western blot and SUMOylated species were detected by probing for SUMO2/3 (Abcam; RRID:[AB_304041](https://scicrunch.org/resolver/AB_304041)).

*Generation of* Trim28^E3MT^ *mice.* {#s3-3}
------------------------------------

*Trim28^E3MT^* mice on a pure C57Bl/6J background were generated via CRISPR/Cas9-mediated gene editing ([@bib28]). Briefly, an sgRNA targeting the 5' of *Trim28* was synthesized by direct PCR from pX330 (gift from Zhang lab, Addgene \#42230) and in vitro transcribed with the MEGAshortscript T7 Transcription kit (Invitrogen) using the following two primers (forward: 5'-TTAATACGACTCACTATAGGGCGTGTGTCGCGAGCGCCTGGTTTTAGAGCTAGAAATAGC-3'; reverse: 5'-AAAAGCACCGACTCGGTGCC-3'). A single stranded oligodeoxynucleotide (ssODN) was purchased from IDT for homologous-directed recombination introducing the C66A, C69A and R72G mutations in Trim28 (5'-CTGCAGCCGCGTCGTCCCCTGCGGGGGGCGGTGGCGAGGCGCAGGAGCTTTTAGAACATGCCGGTGTCGCCAGGGAAGGACTCAGACCAGAACGGGATCCTCGGCTGCTGCCCTGTCTACATTCGGCCTGCAGTGCCTGCCTGGGCCCCGCTACACCCGCCGCAGCGAATAATTCGGGGGATGGCGGCTCGG-3'). The PAM (protospacer adjacent motif) and additional adjacent synonymous mutations were introduced to increase editing efficiency and allow for simple genotyping by differential primer hybridization. On the day of injection, Cas9 protein (PNA Bio), sgRNA and repair template (ssODN) were injected (pronuclear) into ova from C57Bl/6 female mice and transferred into oviducts of pseudopregnant females. The following primers were used to distinguish the E3 mutant allele (forward: 5'-TTGGCGGCGAGCGCACTTGC-3'; reverse: 5'-CCCTGGCGACACCGGCATG-3' or forward: 5'-CATGCCGGTGTCGCCAGGGA-3'; reverse: 5'-TCCCACAGGACATACCTGGTTAGCATCCTGG-3') from the wildtype allele (forward: 5'-TTGGCGGCGAGCGCACTTGC-3'; reverse: 5'-TCGCGACACACGCCGCAGTG-3' or 5'-CACTGCGGCGTGTGTCGCGA-3'; reverse: 5'-TCCCACAGGACATACCTGGTTAGCATCCTGG-3'). Founder mice were backcrossed at least three times prior to experimentation to get rid of potential off-target mutations.

Tamoxifen injections {#s3-4}
--------------------

Tamoxifen injections were performed as previously described ([@bib25]). Briefly, starting at 8--12 weeks of age, tamoxifen or vehicle (peanut oil) was injected intraperitoneally at a dose of 100 mg/kg, three times a week for four weeks. Mice were left to recover for at least two weeks before proceeding with behavioral, biochemical and histological assessment.

AAV generation and P0 injections {#s3-5}
--------------------------------

An AAV8 vector containing both YFP and a miRE cassette-containing shRNA ([@bib8]) under the control of the chicken beta actin (CBA) promoter was generated using Gibson cloning. Individual shRNA sequences were generating using the splaSH algorithm ([@bib20]). Each shRNA vector was tested for efficiency in Neuro2A cells prior to virus generation.

AAV delivery was carried out in neonatal (P0) FVB mouse pups as previously described ([@bib13]). Briefly, neonatal pups (\<8 hr from birth) were separated from lactating dams and anesthetized on ice. 1 × 10^11^ viral genomes were injected per ventricle (total of 2 × 10^11^ genomes per mouse) and mice were left to recover on a heated pad before returning them to their mother. Tissue from the caudal region of the cerebrum (cortex + hippocampus) was harvested ten weeks post injection as this region had the maximal viral expression (YFP positive signal) and offered optimal *Trim28* knockdown by qPCR. RNA extraction was performed using the RNeasy mini kit (Qiagen).

Behavioral analysis {#s3-6}
-------------------

Behavioral analysis was performed by an experimenter blind to the treatment and genotype of the animals. Animal behavior was conducted between 10 am and four pm for each test and was carried out when the animals were 14--22 weeks old (6--10 weeks post tamoxifen injection). The open-field analysis ([@bib17]), parallel rod footslip ([@bib27]), pole test ([@bib22]), elevated plus maze ([@bib17]), conditioned fear ([@bib17]), novel object recognition ([@bib1]), hole poke ([@bib11]) and rotarod ([@bib14]) were performed as previously described. For each test, mice were left to habituate in the testing room with ambient white noise for 30--60 min prior to testing.

Histological analysis {#s3-7}
---------------------

For frozen sections: Free floating sections (25 µm) were mounted and dried on polarized slides (\>48 hr). Slides were then stained for Cresyl violet and GFAP (RRID:[AB_2314539](https://scicrunch.org/resolver/AB_2314539)) as previously described ([@bib21]). For GFAP quantification, photomicrographs were taken using the 10x objective on a Leica DM4000 LED. The percentage of immunoreactive area for GFAP was calculated using ImageJ. Briefly, each DAB-stained image was converted to 8-bit greyscale and made into a binary image using a threshold cutoff of 10% for a representative WT section (after which, the same settings were used for all of the sections in question). Area of interest (Hippocampus or Cortex) was outlined and total area was measured. Within this area, the 'Analyze particles' function was used to determine the area of each outlined immunoreactive entity. The sum of these entities was set at the GFAP positive area and the percentage immunoreactive area was presented as GFAP positive area compared to total area (in %). For cresyl violet staining, the relative width of either the caudal cortex or the CA1 region of the hippocampus was measured in four independent sections.

For paraffin-embedded sections: Formalin-fixed tissues were embedded in paraffin and sectioned on a microtome at 5 µm thickness. Sections were deparaffinized in a series of xylene and ethanol washes before being subjected to antigen retrieval for 10 min at 95°C in a buffer containing 10 mM sodium citrate and 0.02% Tween (pH 6.0). Sections were then blocked for one hour at room temperature in PBS + 0.3% Triton X-100 and 5% FBS and stained in blocking buffer containing either 1:400 anti-GFAP (GA5, Sigma) or 1:500 anti-Trim28 (20C1, Abcam) and corresponding secondary antibodies (Vectastain mouse elite ABC kit or Donkey anti-mouse Alexa 488 secondary; RRID:[AB_2341099](https://scicrunch.org/resolver/AB_2341099)). Fluorescent sections were counterstained using DAPI. Gross morphology was assessed by performing hematoxylin and eosin (H and E) staining using standard protocols.

Mouse blood collection {#s3-8}
----------------------

Mice were anaesthetized with isoflurane and blood was collected from the retro-orbital sinus. A capillary was inserted into the medial canthus of the eye of the anaesthetized mouse. Applying a slight pressure to the capillary allows the blood flow to be directed to a collection tube. After letting the blood coagulate for 30 min, the serum is collected post centrifugation 4 min at 14,000 r.p.m. for analyte analysis with Charles River Laboratories. qPCR analysis qPCR was performed as previously described ([@bib21]). Briefly, 1 µg of RNA isolated from mouse tissue (cortex, hippocampus, midbrain, heart, liver and spleen) was reverse transcribed into cDNA. qPCR primers were designed to span exons to prevent gDNA contamination and can be found in the Key Resources Table. We used the ddCT method as well as S16 as a loading control to calculate relative transcript abundance. Due to the multiple transcript measurements, we used multiple t-tests with an FDR correction of 10% to avoid false discoveries.

Statistical analysis {#s3-9}
--------------------

Experimental analysis was performed in a blinded manner when possible. Statistical tests were performed in accordance with the experimental design. For instance, for simple comparisons we used Student's t-test whereas multi-group analyses we used one- or two-way ANOVA followed by a post-hoc test. For comprehensive statistical coverage of each experiment throughout this manuscript, please see [Supplemental file 1](#supp1){ref-type="supplementary-material"}. In each case, \*, \*\*, \*\*\*, \*\*\*\* and ns denote p\<0.05, p\<0.01, p\<0.001, p\<0.0001 and p\>0.05, respectively.
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Decision letter

Ackerman

Susan L

Reviewing Editor

Howard Hughes Medical Institute, University of California, San Diego

United States

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Depleting Trim28 in adult mice is well tolerated and reduces levels of α-synuclein and tau\" for consideration by *eLife*. Your article has been reviewed by 3 peer reviewers, including a Reviewing Editor, and the evaluation has been overseen by a Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Patrik Verstreken (Reviewer \#2); Ming Guo (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

The manuscript by Rousseaux et al. is a follow up study to the same group\'s *eLife* paper in 2016. In the previous work, Rousseaux demonstrated that the E3 ligase TRIM28 regulates levels of α-synuclein and tau in HEK293T cells, primary mouse neurons and in the mouse hippocampus (via injection of shRNA). Loss of TRIM28 also decreased tau levels in an overexpression fly model and mitigated neurodegenerative phenotypes. Similar findings were observed upon reduction of TRIM28 (via shRNA) in an α-synuclein mouse model. Overexpression of TRIM28 lead to toxic nuclear accumulations of α-synuclein and tau while overexpression of a catalytically inactive TRIM28 (C65A/C68A), while less stable, did not.

In this manuscript, Rousseaux et al. demonstrate that inhibiting UBC9, the sole SUMO ligase, decreased α-synuclein and tau levels. Furthermore, overexpression of TRIM28 increased the SUMOylation of these proteins but expression of C65A/C68A TRIM28 does not. The authors characterized knockin mice heterozygous for the C65A/C68A mutation and found that Trim28 was decreased as were α-synuclein and tau levels. Mice homozygous for this mutation (or for a knockout mutation in Trim28) resulted in embryonic lethality. The authors used both AAV-delivered shRNA and conditional deletion via UBC-CreER to decrease Trim 28 in the postnatal brain. No overt morphological or behavioral phenotypes were observed in these mice suggesting that decreasing Trim28 levels after development might be a safe therapeutic means of decreasing α-synuclein and tau and warrant further investigation.

While the reviewers believe the manuscript is interesting and a valuable continuation of their previous paper, some revisions are necessary prior to publication.

1\) The hypothesis that TRIM28 regulates α-synuclein and tau levels through sumoylation. It is not stated clearly exactly how sumoylation would bring about this regulation. The story with TRIM28 sumo ligase activity appears to be more complicated than indicated in the current manuscript. Trim28 sumo ligase activity has been localized to both the N-terminal Ring domain (mutated in the current and previous paper), and to the C-terminal PHD domain. The latter domain has been implicated in auto-sumoylation as well as sumoylation of other substrates. RING domains can also mediate protein-protein interactions. Thus, experiments in which the RING domain is mutated do not necessarily show that TRIM28 is directly bringing about sumoylation via this domain. It may be a protein-protein interaction domain, or act in other indirect ways.

It is not clear from these experiments (Figure 1B) that the total levels of α-synuclein or tau are significantly altered. In short, while regulation of TRIM28 levels does result in changes in the levels of sumoylated α-synuclein and tau, it is less clear (based on Figure 1bB and C) that total levels are altered. Often sumoylation effects in cells seem to be regulatory, in which a modest fraction of the target protein is modified and then plays a regulatory role, rather than the bulk of the protein being modified, as with ubiquitylation that leads to proteasome-dependent degradation. Thus, I would suggest that the authors consider in their Discussion a variety of models in which the effects of altering TRIM28 activities (binding and ligase activities) are considered together with other models in which sumoylation occurs, but may not necessarily be the primary mechanism by which α-synuclein and tau are being tagged for elimination.

2\) The authors state \"trim28 has several important functions throughout the cell...\" It would be good to include some references, since it has in fact been implicated in a number of important processes. These become important later in the context of considering the consequences of adult-specific downregulation or knockout.

3\) The authors state \"our study suggests that depletion of more than 75% of total TRIM28 from the body is safe\". \"Safe\" seems to be too strong. The authors might consider something more nuanced such as \"our study failed to identify deleterious phenotypes on depletion of more than 75% of total TRIM28 from the body, as determined using a number of assays in multiple tissues. These findings suggest that inhibition of TRIM28 in adulthood may provide a strategy for.... with minimal side effects. TRIM28 has been described to function in a number of contexts, ranging from transposon mobilization, transcriptional regulation, etc... Further characterization of these adult KO animals will provide important insights into the potential of trim28 downregulation to inhibit disease, and any physiological tradeoffs that may be incurred.\" Similarly in the last paragraph of the Results and Discussion. Reference to muscle specific loss of trim28 as safe. Again, \"safe\" may not be the most appropriate word. The paper referenced only notes there is no effect on adiposity. No other data are presented.

4\) A description of the statistical tests used to analyze the data need to be added.

5\) Scale bars should be added to histological images.
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Author response

> \[...\] While the reviewers believe the manuscript is interesting and a valuable continuation of their previous paper, some revisions are necessary prior to publication.
>
> 1\) The hypothesis that TRIM28 regulates α-synuclein and tau levels through sumoylation. It is not stated clearly exactly how sumoylation would bring about this regulation. The story with TRIM28 sumo ligase activity appears to be more complicated than indicated in the current manuscript. Trim28 sumo ligase activity has been localized to both the N-terminal Ring domain (mutated in the current and previous paper), and to the C-terminal PHD domain. The latter domain has been implicated in auto-sumoylation as well as sumoylation of other substrates. RING domains can also mediate protein-protein interactions. Thus, experiments in which the RING domain is mutated do not necessarily show that TRIM28 is directly bringing about sumoylation via this domain. It may be a protein-protein interaction domain, or act in other indirect ways.

We have further expanded on our rationale for studying α-Syn and tau SUMOylation over other potential effects in the first paragraph of the Results and Discussion. In hindsight, we agree that the relationship between TRIM28 and α-Syn and tau is likely not as clear-cut as it seems (Results and Discussion, second paragraph). We have therefore highlighted this at the end of our Discussion (subsection "SUMOylation assays", first paragraph).

> It is not clear from these experiments (Figure 1B) that the total levels of α-synuclein or tau are significantly altered. In short, while regulation of TRIM28 levels does result in changes in the levels of sumoylated αB and C) that total levels are altered. Often sumoylation effects in cells seem to be regulatory, in which a modest fraction of the target protein is modified and then plays a regulatory role, rather than the bulk of the protein being modified, as with ubiquitylation that leads to proteasome-dependent degradation. Thus, I would suggest that the authors consider in their Discussion a variety of models in which the effects of altering TRIM28 activities (binding and ligase activities) are considered together with other models in which sumoylation occurs, but may not necessarily be the primary mechanism by which α-synuclein and tau are being tagged for elimination.

To this second point, we wish to clarify that the amounts of α-Syn and tau that are pulled down in these assays (Figure 1B and C) are non-saturating. Therefore, when looking at the IP conditions, one does not expect to see changes in α-Syn and tau levels following TRIM28 modulation. These "sub-threshold pulldowns" allow for easier interpretation of SUMOylation data (the numerator) as the candidate immunoprecipitated (the denominator) is constant. Thus, from these results, we cannot comment as to the effect on α-Syn and tau levels but instead we can only comment on the effect of TRIM28 on their SUMOylation status.

> 2\) The authors state \"trim28 has several important functions throughout the cell...\" It would be good to include some references, since it has in fact been implicated in a number of important processes. These become important later in the context of considering the consequences of adult-specific downregulation or knockout.

We have included references that highlight the multiple functions of TRIM28 in the cell.

> 3\) The authors state \"our study suggests that depletion of more than 75% of total TRIM28 from the body is safe\". \"Safe\" seems to be too strong. The authors might consider something more nuanced such as \"our study failed to identify deleterious phenotypes on depletion of more than 75% of total TRIM28 from the body, as determined using a number of assays in multiple tissues. These findings suggest that inhibition of TRIM28 in adulthood may provide a strategy for.... with minimal side effects. TRIM28 has been described to function in a number of contexts, ranging from transposon mobilization, transcriptional regulation, etc. Further characterization of these adult KO animals will provide important insights into the potential of trim28 downregulation to inhibit disease, and any physiological tradeoffs that may be incurred.\" Similarly in the last paragraph of the Results and Discussion. Reference to muscle specific loss of trim28 as safe. Again, \"safe\" may not be the most appropriate word. The paper referenced only notes there is no effect on adiposity. No other data are presented.

We agree that without complete longitudinal characterization of these mice, using the term "safe" may be premature. Thus, we have reworded the text to reflect our observations as per the reviewers' suggestions (Results and Discussion, seventh paragraph).

> 4\) A description of the statistical tests used to analyze the data need to be added.

We have now included a brief description of the statistical tests used in the Materials and methods and have now incorporated all statistical tests used throughout the study as Supplementary file 1.

> 5\) Scale bars should be added to histological images.

These have been added.

[^1]: Department of Cellular and Molecular Medicine, University of Ottawa Brain and Mind Research Institute, University of Ottawa, Ontario, Canada.
